Sutro Biopharma (STRO) Operating Leases (2021 - 2026)

Sutro Biopharma has reported Operating Leases for 5 years, with the latest figure at $7.9 million in Q4 2025.

• Quarterly Operating Leases fell 49.66% year-over-year to $7.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.9 million (down 49.66% YoY) and the FY2025 annual result came in at $7.9 million, down 49.66% from the prior year.
• Operating Leases eased to $7.9 million in Q4 2025 per STRO's latest filing, from $9.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $32.1 million in Q3 2021 and troughed at $7.9 million in Q4 2025.
• A 5-year average of $22.6 million and a median of $24.0 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases slipped 3.23% in 2022, then plunged 49.66% in 2025.
• Over 5 years, Operating Leases stood at $31.2 million in 2021, then slipped by 5.28% to $29.6 million in 2022, then slipped by 21.71% to $23.2 million in 2023, then slumped by 32.31% to $15.7 million in 2024, then slumped by 49.66% to $7.9 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $7.9 million, $9.7 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.